Related Experiment Videos
Targeting primary Sjögren's syndrome
Toshio Odani1, John A Chiorini1
1a Adeno-Associated Virus Biology Section, Molecular Physiology and Therapeutics Branch , National Institute of Dental and Craniofacial Research, National Institutes of Health , Bethesda , MD , USA.
Modern Rheumatology
|November 15, 2018
Summary
Primary Sjögren's syndrome (pSS) is an autoimmune condition affecting millions globally. This review explores current and emerging targeted therapies for pSS, addressing limited treatment options and improving patient quality of life.
Area of Science:
- Immunology
- Rheumatology
- Autoimmune Diseases
Background:
- Primary Sjögren's syndrome (pSS) is a chronic autoimmune disease impacting salivary and lacrimal glands.
- Key features include lymphocytic infiltration, elevated cytokines, autoantibodies, fatigue, and reduced quality of life.
- A significant percentage of pSS patients develop extra-glandular manifestations, including lymphoma.
Purpose of the Study:
- To review current therapeutic strategies for pSS.
- To discuss emerging targeted therapies for pSS.
- To highlight advancements in treating systemic manifestations and dryness in pSS.
Main Methods:
- Literature review of current and emerging pSS therapies.
- Analysis of targeted treatments focusing on specific immune pathways.
- Synthesis of information on managing dryness and systemic symptoms.
Main Results:
- Current pSS treatments offer limited efficacy for both local and systemic symptoms.
- New therapies targeting specific immune pathways are under development.
- Focus is shifting towards precision medicine for pSS management.
Conclusions:
- Effective treatments for pSS remain limited, necessitating novel therapeutic approaches.
- Targeted therapies hold promise for improving outcomes in pSS patients.
- Future research should focus on developing and validating these new treatments to enhance patient quality of life.